Applications Vaccixcell

Gene Therapy

Large scale AAV Virus Packaging

Esco VacciXcell envisions a world of easy access to cost-effective large/small scale AAV Virus packaging for all nations in the form of gene therapy.

Gene Therapy Page

Gene therapy is the introduction of genetic material into a host cell to treat or prevent a disease. It uses sections of DNA (usually genes) to replace the mutated gene and change the expression of protein(s) critical to the development and progress of the disease.

Several approaches to gene therapy

  • Replacing a mutated gene that causes disease with a healthy copy of the gene.
  • Inactivating, or “knocking out,” a mutated gene that is not functioning properly.
  • Introducing a new gene into the body to help fight a disease.

The genetic material can be delivered directly as DNA or DNA complexes (non-viral methods) or packaged within a viral vector (recombinant virus) to efficiently taken up by appropriate cells. There are different viruses that can be used for human gene therapy as viral vectors, including retrovirus, adenovirus, lentivirus, herpes simplex, vaccinia and adeno-associated virus.

Adeno-associated Virus (AAV) have a single strand of DNA, which can infect humans and some other primate species without causing any disease and has very mild immune response. Also, it has the ability to integrate its genome to the host cell and duplicate itself after the infection. Due to these properties, AAV can be an effective tool for gene transfer and viral vector for gene therapy. HEK293T cells have been used to produce rAAV vectors in many clinical trials for gene therapy. Phase 1 and Phase 2 clinical trials for diseases such as Parkinson’s disease, Hemophilia B, Arthritis and CFTR using this treatment method has yielded promising results.

HEK 293 cells are anchorage-dependent cells that originate from the embryonic kidney of a human fetus. The HEK-293 cell line has been widely used for the biotechnology industry to produce therapeutic proteins and viruses for gene therapy. Particularly, VacciXcell’s tide motion bioreactor system has been used to successfully produce recombinant proteins from recombinant HEK-293 cells and adenovirus production.

Esco VacciXcell Advantage

Esco VacciXcell offers a wide range of bioreactors and fermenters that can produce recombinant DNA, recombinant viruses, miRNA adenoviruses, full-length ORF adenoviruses from different cell lines of mammalian cells, insect cells, etc.

Esco Vaccixcell tidemotion bioreactors, CelCradle and TideCell®  are proven systems in culturing adherent cells such as HEK293. Our patented tidemotion technology along with proprietary BioNOC II macrocarriers ensures that the cells attach and stays attach during inoculation and culture process. The gentle tidemotion provides unlimited oxygenation and nutrion while virtually eliminating shear stress. Being the only TRUE LINEARLY SCALABLE system, from 0.5 L to 5,000 L, in the market, Esco Vaccixcell’s tidemotion bioreactor reduces cost, labor requirement and bioprocessing time.

Esco VacciXcell's Tide Motion System is the highest yield and lowest cost packed bed bioreactor system and the only packed bed bioreactor that can be placed inside a cGMP isolator, making it an ideal system for the production of wild-type viruses.

On top of this, Esco VacciXcell can provide turnkey solutions for the gene therapy industry, beginning from research and development, all the way to the production scale of the end product.